Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
Open accessAbstract
High Resolution Image Download MS PowerPoint Slide Chemistry42 is a software platform for de novo small molecule design and optimization that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methodologies. Chemistry42 efficiently generates novel molecular structures with optimized properties validated in both in vitro and in vivo studies and is available through licensing or collaboration. Chemistry42 is the core component of Insilico Medicine’s Pharma.ai drug discovery suite. Pharma.ai also includes PandaOmics for target discovery and multiomics data analysis, and inClinico─a data-driven multimodal forecast of a clinical trial’s probability of success (PoS). In this paper, we demonstrate how the platform can be used to efficiently find novel molecular structures against DDR1 and CDK20.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764 · see citing works
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139 · see citing works
Kohonen, T. (1995) · Springer series in information sciences · doi:10.1007/978-3-642-56927-2 · Cited by 16,032 · see citing works
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,963 · see citing works
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770 · see citing works
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · see citing works
Self-citationGenerating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537 · see citing works
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X. Y., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,045 · see citing works
Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models
Polykovskiy, D., Zhebrak, A., Sanchez-Lengeling, B., Golovanov, S., Tatanov, O., Belyaev, S., Kurbanov, R., Artamonov, A., Aladinskiy, V., Veselov, M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565644 · Cited by 849 · see citing works
Self-citationPDB-wide collection of binding data: current status of the PDBbind database
Liu, Z., Li, Y., Han, L., Li, J., Liu, J., Zhao, Z., Nie, W., Liu, Y., & Wang, R. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu626 · Cited by 650 · see citing works
Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00346 · Cited by 587 · see citing works
Self-citationPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D. H., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 507 · see citing works
Reinforced Adversarial Neural Computer for de Novo Molecular Design
Lane, E., Asadulaev, A., Ivanenkov, Y. A., Aladinskiy, V., Sánchez-Lengeling, B., Aspuru‐Guzik, A., & Zhavoronkov, A. A. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00690 · Cited by 381 · see citing works
Self-citation<i>De Novo</i> Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373 · see citing works
Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365 · see citing works
Self-citationKadurin, A., Aliper, A., Kazennov, A., Mamoshina, P., Vanhaelen, Q., Khrabrov, K., & Zhavoronkov, A. (2017) · Oncotarget · doi:10.18632/oncotarget.14073 · Cited by 350 · see citing works
Self-citationRavi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325 · see citing works
Self-citationEntangled Conditional Adversarial Autoencoder for de Novo Drug Discovery
Polykovskiy, D., Zhebrak, A., Vetrov, D., Ivanenkov, Y., Aladinskiy, V., Mamoshina, P., Bozdaganyan, M., Aliper, A., Zhavoronkov, A., & Kadurin, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00839 · Cited by 278 · see citing works
Self-citationEvolutionary algorithms for de novo drug design – A survey
Devi, R. V., Sathya, S. S., & Coumar, M. S. (2014) · Applied Soft Computing · doi:10.1016/j.asoc.2014.09.042 · Cited by 151 · see citing works
The Advent of Generative Chemistry
Vanhaelen, Q., Lin, Y.-C., & Zhavoronkov, A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00088 · Cited by 151 · see citing works
Self-citationBioisosteres in Medicinal Chemistry
(2012) · Wiley eBooks · doi:10.1002/9783527654307 · Cited by 147 · see citing works
Ozerov, I. V., Lezhnina, K. V., Izumchenko, E., Artemov, A. V., Medintsev, S., Vanhaelen, Q., Aliper, A. M., Vijg, J., Osipov, A. N., Labat, I., et al. (2016) · Nature Communications · doi:10.1038/ncomms13427 · Cited by 136 · see citing works
Self-citationIvanenkov, Y. A., Zagribelnyy, B. A., & Aladinskiy, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00004 · Cited by 123 · see citing works
Self-citationPrivileged Structures in Drug Discovery
Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263 · Cited by 108 · see citing works
Enhancing Molecular Shape Comparison by Weighted Gaussian Functions
Yan, X., Li, J., Liu, Z., et al. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300601q · Cited by 84 · see citing works
Immune profiles in primary squamous cell carcinoma of the head and neck
Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I. V., Zhavoronkov, A. A., Sidransky, D., Bedi, A., Hoque, M. O., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.032 · Cited by 72 · see citing works
Self-citationMolGrow: A Graph Normalizing Flow for Hierarchical Molecular Generation
Kuznetsov, M., & Polykovskiy, D. A. (2021) · AAAI Publications (The Association for the Advancement of Artificial Intelligence (AAAI)) · doi:10.1609/aaai.v35i9.17001 · Cited by 44 · see citing works
Self-citationHas Drug Design Augmented by Artificial Intelligence Become a Reality?
Chen, H., & Engkvist, O. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.004 · Cited by 40 · see citing works
Generative Models for Artificially‐intelligent Molecular Design
Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201880131 · Cited by 37 · see citing works
Stamatas, G. N., Wu, J., Pappas, A., Mirmirani, P., McCormick, T. S., Cooper, K. D., Consolo, M. C., Schastnaya, J., Ozerov, I. V., Aliper, A. M., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1327492 · Cited by 26 · see citing works
Self-citationSubbannayya, T., Leal, P., Zhavoronkov, A. A., et al. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-00503-5 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02143-0 · Cited by 348 · see citing works
“Given the scarcity of anti-fibrotic therapies for IPF or CKD, we used our published generative AI pipeline 14,15,40–42 to address this clinical need.”
InfluentialSelf-citationAI-powered therapeutic target discovery
Pun, F. W., Ozerov, I. V., & Zhavoronkov, A. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.010 · Cited by 341 · see citing works
Self-citationArtificial Intelligence for Drug Discovery: Are We There Yet?
Hasselgren, C., & Oprea, T. I. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040323-040828 · Cited by 236 · see citing works
“Designed using the PandaOmics (158) and Chemistry42 (159) platforms, ISM018-055, which may be covered by this patent (160), targets NCK-interacting protein kinase, TNIK (http://bit.ly/insmhkexa1) and is indicated for the treatment of idiopathic pulmonary fibrosis.”
BackgroundQuantum computing for near-term applications in generative chemistry and drug discovery.
Pyrkov, A., Aliper, A., Bezrukov, D., Lin, Y.-C., Polykovskiy, D., Kamya, P., Ren, F., & Zhavoronkov, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103675 · Cited by 100 · see citing works
Self-citation
- Authors
- Ivanenkov, Y. A., Polykovskiy, D., Bezrukov, D., Zagribelnyy, B., Aladinskiy, V., Kamya, P., Aliper, A., Ren, F., & Zhavoronkov, A.
- Affiliations
- Insilico Medicine Kong Kong Ltd., Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, Hong Kong
- Insilico Medicine Canada Inc., 3710-1250 René-Lévesque Blvd W, Montreal, Quebec, H3B 4W8 Canada
- Insilico Medicine AI Limited, Level 6, Unit 08, Block A, IRENA HQ Building, Masdar City, PO Box 145748, Abu Dhabi, UAE
- Insilico Medicine Shanghai Ltd., Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China
- Corresponding author
- Zhavoronkov, Alex
- ORCID
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-02-02
- Volume
- 63
- Issue
- 3
- Pages
- 695-701
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- PMC
- PMC9930109
- OpenAlex
- W4318912574
- Cited by
- 231
- References
- 31
- Citations by year
- 2026: 71 · 2025: 78 · 2024: 61 · 2023: 19 · 2022: 1 · 2021: 1
- FWCI
- 32.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Chemical Information and Modeling (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Keywords
- de novo molecular design, small molecule design, artificial intelligence in drug discovery, molecular optimization, DDR1
- MeSH terms
- Artificial Intelligence, Software, Drug Design, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review